GlassScriptPhysician profile
Leonard C Salvia
NPI 1154314649
$5,237.68
in general payments reported to CMS, 2019-2025
31 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $347 · 2021: $442 · 2022: $997 · 2023: $911 · 2024: $1,015 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $626.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $431.40 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $424.57 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $422.15 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $370.62 | 2019-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $356.14 | 2023-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $315.19 | 2019-2025 | Lifevest |
| Astellas Pharma US INC | $258.67 | 2019-2020 | |
| Pfizer INC. | $258.06 | 2019-2025 | |
| Amgen INC. | $245.43 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.92 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $197.44 | 2019-2024 | Brilinta, Farxiga |
| Actelion Pharmaceuticals US, INC. | $183.68 | 2019-2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $96.76 | 2022-2023 | Arcalyst |
| Boston Scientific Corporation | $92.81 | 2020-2025 | Watchman Access System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $82.28 | 2024 | |
| Alnylam Pharmaceuticals INC. | $79.85 | 2023-2025 | Onpattro |
| Baxter Healthcare | $76.86 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Edwards Lifesciences Corporation | $70.19 | 2022-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kestra Medical Technology Services, INC. | $51.27 | 2023-2025 | Assure Wcd |
| Abbott Laboratories | $48.98 | 2025 | Amplatzer Amulet, Cardiomems |
| Philips North America LLC | $45.82 | 2022 | |
| Scpharmaceuticals INC. | $45.09 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $42.21 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $38.63 | 2019 | |
| Impulse Dynamics (USA) INC. | $27.09 | 2024 | Optimizer |
| Vivaquant INC, Dba Rhythm Express | $26.96 | 2024-2025 | Rhythm Express, Rhythm Express |
| Medtronic, INC. | $26.49 | 2021-2022 | |
| Bridgebio Pharma, INC. | $24.01 | 2025 | Attruby |
| Amarin Pharma, INC. | $17.38 | 2020 | |
| Bardy Diagnostics, INC. | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Salvia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.